“用于治疗乳腺癌的新型苯基喹啉衍生物的设计和合成：靶向c-Myc g -四重体”的更正[欧洲]。医学化学，291 (2025)117663]

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-05-08 DOI:10.1016/j.ejmech.2025.117719

Xutong Wang, Yu Liu, Zeyu Gao, Xiaodong Fang, Kejing Ma, Meng Sun, Qiming Li, Bing Wang, Yong Zhang, Xin Zhao, Weina Han

{"title":"“用于治疗乳腺癌的新型苯基喹啉衍生物的设计和合成：靶向c-Myc g -四重体”的更正[欧洲]。医学化学，291 (2025)117663]","authors":"Xutong Wang, Yu Liu, Zeyu Gao, Xiaodong Fang, Kejing Ma, Meng Sun, Qiming Li, Bing Wang, Yong Zhang, Xin Zhao, Weina Han","doi":"10.1016/j.ejmech.2025.117719","DOIUrl":null,"url":null,"abstract":"The authors regret that during the post-publication review showed that the Western Blot bands in Fig. 11D were pasted incorrectly, which was caused by the mismatch of file versions during the revision process. Corrected Fig. 11 are listed below.<figure><img alt=\"Fig. 11\" aria-describedby=\"cap0010\" height=\"509\" src=\"https://ars.els-cdn.com/content/image/1-s2.0-S0223523425004842-fx1.jpg\"/><ol><li>Download: Download high-res image (1MB)</li><li>Download: Download full-size image</li></ol>Fig. 11. Evaluation of the anticancer activity of W11 in human breast cancer xenografts. (A) Digital photos of mice in the control group, drug-treated group and positive control group on the 21st day of treatment. (B) Digital photos and average weight data of tumor tissue samples. (C) Fluorescence imaging of live animals in the control group, drug-treated group, and positive control group after 21 days of treatment. (D) Expression of c-Myc protein in tumor tissues of the control group, drug-treated group and positive control group after 21 days of treatment. (N ≥ 4; mean ± SD; (∗) P < 0.05, (∗∗) P < 0.01, and (∗∗∗) P < 0.001, significantly different from the control; ns, not significantly different from the control).</figure>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"25 1","pages":"117719"},"PeriodicalIF":6.0000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Design and synthesis of novel styrylquinolinium derivatives for the treatment of breast cancer: Targeting the c-Myc G-Quadruplex” [Europ. J. Med. Chem. 291 (2025) 117663]\",\"authors\":\"Xutong Wang, Yu Liu, Zeyu Gao, Xiaodong Fang, Kejing Ma, Meng Sun, Qiming Li, Bing Wang, Yong Zhang, Xin Zhao, Weina Han\",\"doi\":\"10.1016/j.ejmech.2025.117719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The authors regret that during the post-publication review showed that the Western Blot bands in Fig. 11D were pasted incorrectly, which was caused by the mismatch of file versions during the revision process. Corrected Fig. 11 are listed below.<figure><img alt=\\\"Fig. 11\\\" aria-describedby=\\\"cap0010\\\" height=\\\"509\\\" src=\\\"https://ars.els-cdn.com/content/image/1-s2.0-S0223523425004842-fx1.jpg\\\"/><ol><li>Download: Download high-res image (1MB)</li><li>Download: Download full-size image</li></ol>Fig. 11. Evaluation of the anticancer activity of W11 in human breast cancer xenografts. (A) Digital photos of mice in the control group, drug-treated group and positive control group on the 21st day of treatment. (B) Digital photos and average weight data of tumor tissue samples. (C) Fluorescence imaging of live animals in the control group, drug-treated group, and positive control group after 21 days of treatment. (D) Expression of c-Myc protein in tumor tissues of the control group, drug-treated group and positive control group after 21 days of treatment. (N ≥ 4; mean ± SD; (∗) P < 0.05, (∗∗) P < 0.01, and (∗∗∗) P < 0.001, significantly different from the control; ns, not significantly different from the control).</figure>\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":\"25 1\",\"pages\":\"117719\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejmech.2025.117719\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.117719","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

遗憾的是，在发表后复查中发现图11D中的Western Blot条带粘贴错误，这是由于修改过程中文件版本不匹配造成的。修正后的图11列在下面。下载：下载高分辨率图片（1MB）下载：下载全尺寸图片11. W11在人乳腺癌异种移植物中的抗癌活性评价。(A)治疗第21天，对照组、药物治疗组和阳性对照组小鼠的数码照片。(B)肿瘤组织样本的数码照片及平均重量数据。(C)治疗21 d后，对照组、药物治疗组和阳性对照组活体动物荧光成像。(D)治疗21 D后，对照组、药物治疗组和阳性对照组肿瘤组织中c-Myc蛋白的表达情况。(n≥4；平均值±SD；（∗）P <；0.05,(∗∗)P <；0.01,(∗∗)P <；0.001，与对照组有显著差异；n，与对照组没有显著差异)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Corrigendum to “Design and synthesis of novel styrylquinolinium derivatives for the treatment of breast cancer: Targeting the c-Myc G-Quadruplex” [Europ. J. Med. Chem. 291 (2025) 117663]

The authors regret that during the post-publication review showed that the Western Blot bands in Fig. 11D were pasted incorrectly, which was caused by the mismatch of file versions during the revision process. Corrected Fig. 11 are listed below.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.